GAMBARAN KETAHANAN HIDUP (KESINTASAN) SATU TAHUN PASIEN KOINFEKSI TB-HIV BERDASARKAN WAKTU AWAL PENGOBATAN ANTIRETROVAL (ARV) PADA FASE LANJUT DI RUMAH SAKIT PENYAKIT INFEKSI (RSPI) PROF. DR. SULIANTI SAROSO PERIODE JANUARI 2011-MEI 2014

Abstract Background : Human Immunodeficiency Virus (HIV) is a type of retrovirus that infects the human immune system that causes Acquired Immunodefiency Syndrome (AIDS). The presence of TB germs cause progression of cases of co-infection of TB-HIV getting worse so threatening sufferers. This study aims to reveal the one-year survival rate of patients co-infected TB-HIV based on time start of antiretroviral treatment. Methods : This study used a retrospective cohort design in RSPI Prof. Dr. Sulianti Saroso years 2013-2015. The data used comes from searches on the register of pre ARV and ARV form, TB Form, the book ARV monitoring, monitoring of pharmaceutical drugs, ARV overview and status tracking of medical records. The data collection involves the officer HIV / AIDS and the doctor (validation diagnosis and covariates) were in blind on the research hypothesis. Results : The cumulative probability of survival for one year patients co-infected TB-HIV get antiretroviral treatment early in RSPI Prof. Dr. Sulianti Saroso period January 2011-May 2014 was 81.5%. The probability of survival for patients of TB-HIV based on the initial time showed that one-year survival in patients receiving antiretroviral treatment in the intensive phase was 89.1% and in patients receiving antiretroviral treatment in advanced phases was 74.5%. Conclusion : Co-infected TB-HIV patients get antiretroviral drugs in the intensive phase tend to have a probability of survival is greater in the first year compared to co-infection TB-HIV patients get antiretroviral drugs in the advanced phase